A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

EndoClot ® SIA Receives FDA Clearance

First Starch-Derived Submucosal Injection System Cleared in the U.S. Market for Endoscopic Removal of Polyps, Adenomas, Early Stage Cancers and other GI mucosal Lesions Expected to be Commercially Available in the United States Beginning May 2020

EndoClot® SIA is the first starch-derived submucosal injection system cleared in the U.S. market for endoscopic removal of polyps, adenomas, early-stage cancers, and other gastrointestinal mucosal lesions.

Starch-based polysaccharide has a long history of clinical applications with an excellent safety profile. A specially designed spiral injection syringe is included in the single-use kit for ease of delivering the solution.

“EndoClot® SIA enables longer-lasting and higher mucosal elevation with clearer margins than saline and therefore enables more precise and effective removal of the lesion,” said Steve Heniges, President of EPI. “It also increases the safety cushion by creating a greater margin between the mucosa to be resected and the muscle layer to be protected due to the viscosity of the solution. This is very important as it reduces complications and enables the Gastroenterologist to remove the lesions efficiently.”

EPI will utilize its established distribution network along with new strategic partners to bring this innovative product to the GI Endoscopy market.

EndoClot Plus is focused on utilizing its polymer expertise to develop customized medical devices to meet GI clinical needs. With its innovative technology platforms, EndoClot Plus aims to become the leading company in creating new biomaterial therapeutic solutions for GI Endoscopy.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Serum Detect is developing diagnostic tests, using standard liquid biopsy samples, that complement and enhance existing screening techniques for early detection of cancer.
The company announced the launch of validated antibodies for rare cell and circulating tumor cell (CTC) enumeration. Validated for use with Bio-Rad’s Celselect Slides Enumeration Stain Kits, the antibodies are specific to CTC surface markers to enable the sensitive and specific identification of target cell populations, enhancing the study of tumor heterogeneity and disease progression at various stages.
Proteintech advises the new building houses research and development, production, logistics and administration in an area more than three times larger than its previous space.
In September 2023, Seegene and Springer Nature opened applications to scientists and experts across the global community to conduct research for the 15 designated projects to develop Seegene's syndromic qPCR diagnostics assay reagents for the Open Innovation Program.
Lindus Health has taken learnings from this experience to build a bespoke "All-in-One Metabolic CRO" offering that combines the expertise of a seasoned full service CRO and internal site/PI expertise with a distinctive technology driven approach on its proprietary Citrus™ platform. This unique marriage of technology and services sets metabolic sponsors up to run faster, more patient-centric clinical trials.

By using this website you agree to accept Medical Device News Magazine Privacy Policy